Search

Author/Creator Charokopou, M.

1. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. (1st December 2016)

Authors:
Chuang, L. H.; Verheggen, B. G.; Charokopou, M.; Gibson, D.; Grandy, S.; Kartman, B.
Journal:
Journal of medical economics
Issue:
Volume 19:Number 12(2017)
Page Start:
1127
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective. Issue 1 (June 2015)

Authors:
Charokopou, M.; McEwan, P.; Lister, S.; Callan, L.; Bergenheim, K.; Tolley, K.; Postema, R.; Townsend, R.; Roudaut, M.
Journal:
BMC health services research
Issue:
Volume 15:Issue 1(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013. (1st February 2016)

Authors:
Charokopou, M.; Sabater, F.J.; Townsend, R.; Roudaut, M.; McEwan, P.; Verheggen, B.G.
Journal:
Current medical research and opinion
Issue:
Volume 32:Number 2(2016:Feb.)
Page Start:
207
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗